Family *Filoviridae*, genus *Ebolavirus* (EBOV) causes severe viral hemorrhagic fever in humans and other primates ([@bib0035]). Previous outbreaks of EBOV in central Africa are associated with serious public health problems. Indeed, since its identification in 1976 during an outbreak in Zaire ([@bib0145]), there have been over 20 outbreaks of EBOV in Africa ([@bib0020]). 2332 cases were reported between 1976 and 2012 and 1526 patients died. 11,325 of 28,652 patients died in EBOV outbreak that occurred in 2014 ([@bib0015]). 25--90% of patients infected with EBOV die. The Ebola virus variant *Makona* was the causative agent of the recent outbreak of Ebola during 2014 to 2016 in West Africa, which was the largest outbreak to date. The recently isolated EBOV *Makona* variant, from a clinical case of EBOV disease (EVD) in *Makona*, has been shown to have a varying case fatality rate (CFR) of 70--50% at later stages of the outbreak ([@bib0140]). Therefore, in this study, we applied S2 cells for production of species *Zaire ebolavirus*, strain *Makona* (EBOV *Makona)* VLPs using the *Makona* outbreak strain.

EBOV belongs to the *Filoviridae* family and contains single-stranded, negative-sense RNA genome of 19 kb. The particles resemble long, stretched filaments and consist of three compartments, including the nucleocapsid (NP), matrix space, and envelope. Additionally, the particles measure 80 nm in diameter and range from 600 to 1400 nm in length. The genome of EBOV contains seven genes, which encode GP, NP, VP24, VP40, VP30, VP35, and L proteins ([@bib0095]; [@bib0025]).

Virus-like particles (VLPs) mimic the structure of virions and have nonreplicating, noninfective properties because the particles lack the infectious genome and are only composed of structural or capsid proteins ([@bib0055]). VLP-based vaccines are safe and high immunogenic. Moreover, VLPs stimulate innate and humoral immunity and activate antigen presentation in antigen-presenting cells ([@bib0080]). The development of vaccine candidates derived from VLPs may be a promising approach for efficient antibody production. Indeed, several VLP vaccine candidates for a variety of viruses have been developed. Vaccines based on VLPs for hepatitis B virus (HBV), papillomavirus, and influenza virus A have been evaluated in clinical trials in human or have been approved for clinical use ([@bib0105]; [@bib0080]).

VLPs are produced in several systems, including bacteria, mammalian cells, yeast, plants, and insect cells. Insect system is a promising system for high yield and rapid production of VLPs ([@bib0115]). Moreover, insect systems can induce post-translational modifications similar to mammalian cells, facilitating the assembly of VLPs ([@bib0030]; [@bib0070]). VLP-based vaccines, including hepatitis C virus (HCV), papillomavirus, enterovirus type 71 A (EV71), influenza virus A, and SARS-coronavirus (CoV), have been developed in insect systems ([@bib0010]; [@bib0005]; [@bib0060]; [@bib0100]; [@bib0075]; [@bib0040]). Additionally, Sf9 insect cells have been used for production of recombinant baculovirus-based VLPs ([@bib0130],[@bib0135]; [@bib0045]; [@bib0120]).

*Drosophila melanogaster* Schneider (S2) cells have been used for efficient expression of protein. Because of their rapid growth, these cells can be used for large-scale VLP production. Ectopic overexpression of human immunodeficiency virus (HIV)-1 envelope protein in S2 cells results in a high yield of HIV-1 VLPs and proper cleavage of envelope precursor protein ([@bib0150]). In a previous study, VP2/6 double-layered rotavirus-like particles containing Wa capsid protein were produced in S2 cells transformed with a bicistronic expression system consisting of encephalomyocarditis virus (EMCV)-derived internal ribosomal entry site (IRES) element ([@bib0065]).

Glycoprotein (GP), nucleoprotein (NP), minor matrix protein (VP) 24, and VP40 originating from EBOV *Makona* was artificially synthesized. The amplified inserts were cloned into the *Bgl*II and *Xba*I sites of the plasmid pMT/V5/His (Invitrogen, Carlsbad, CA, USA) and were confirmed by sequencing. NP, GP, and VP24 of Ebola virus have been shown to facilitate assembly and release of VP40 eVLPs ([@bib0050]). Therefore, to assess EBOV protein expression, *Drosophila* S2 cells were transfected with EBOV plasmids using transfection reagent (TranIt-2020; Mirus, USA); at 24 h before harvesting, cells were treated with 250 μM CuSO~4~ to induce protein expression. The cells and culture supernatants were harvested, and EBOV protein expression was confirmed by immunoblot analysis. The cells were lysed in RIPA buffer (Invitrogen) for 15 min on ice, and lysates were collected after centrifugation at 12,000 rpm for 10 min at 4 °C. The culture supernatants were collected and concentrated using a 30 kDa Centrifugal Filter with Ultracel-30 membrane (Millipore, Germany). To visualize the released particles, the concentrated supernatants were centrifugated through 25% sucrose and then negatively stained. The cell lysates and concentrated supernatants were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis after heating at 70 °C for 10 min, and the proteins were electrotransferred to polyvinylidene difluoride membranes. The membranes were blocked in TBS/Tween solution containing 5% skim milk for 1 h at room temperature. The membranes were then incubated with primary anti-V5 (Invitrogen), anti-NP (Alpha Diagnostics, USA), anti-VP40 (Cosmo Genetech, South Korea), and anti-GP antibodies for 1 h at room temperature, washed three times with TBS/Tween solution, and incubated with secondary anti-mouse-AP, anti-rabbit-AP, or anti-human-AP antibodies for 1 h at room temperature. Finally, membranes were washed three times, and proteins were detected using a BCIP/NBT substrate kit (Invitrogen). As shown in [Fig. 1](#fig0005){ref-type="fig"} A, we confirmed that Ebola viral proteins were efficiently expressed in EBOV *Makona*-transfected S2 cells. The formation of VLPs similar to Ebola virus particles was visualized in both EBOV *Makona-*transfected S2 cells and culture supernatant by transmission electron microscopy (TEM; [Fig. 1](#fig0005){ref-type="fig"}B). As negative control for VLPs formation, we used cells which were transfected with GP, NP, and VP24 without VP40. As shown in [Fig.1](#fig0005){ref-type="fig"}B, filamentous particles of approximately 50 nm in diameter and 1400 nm in length were observed in culture supernatant of EBOV *Makona*-transfected S2 cells.Fig. 1(A) Expression of EBOV *Makona* protein in S2 cells. S2 cells were transfected with GP, NP, VP24, and VP40 of EBOV *Makona*. At 48 h or 72 h post-transfection, expression of proteins in cell lysates was analyzed by immunoblotting. Mock indicates non-transfected cells (B) Transmission electron microscopy of eVLPs. S2 cells were transfected with EBOV *Makona*. At 72 h post-transfection, the formation of VLPs in both cells and culture supernatant was analyzed by transmission electron microscopy. Negative indicates cells transfected with GP, NP, and VP24 without VP40. Scale bars: Mock, 500 nm; Negative, 200 nm; EBOV *Makona*, 200 nm and 500 nm.Fig. 1

Next, the harvested cells were disrupted by repeated freezing and thawing three times, and the debris was removed after centrifugation at 10,000×*g* for 10 min. Cell lysates collected by centrifugation were overlaid on top of a continuous sucrose gradient (80%, 60%, 40%, 30%, and 20%) and ultracentrifuged at 35,000 rpm for 4 h at 4 °C using a SW41Ti rotor (Beckman, USA). The procedure for sucrose gradient ultracentrifugation is illustrated in [Fig. 2](#fig0010){ref-type="fig"} A. To analyze the production of eVLPs, 12 fractions were collected from top to bottom, and the expression of EBOV proteins was confirmed by immunoblotting. As shown in [Fig. 2](#fig0010){ref-type="fig"}B, abundant amounts of EBOV proteins were detected in fractions 8 and 9. From this result, we found that eVLPs were mainly concentrated in fractions 8 and 9. We then aimed to recover the eVLPs. To this end, fractions 8 and 9 were overlaid on top of a 25% sucrose cushion and ultracentrifuged at 25,000 rpm for 1 h at 4 °C using a SW41Ti rotor (Beckman). The pelleted eVLPs were resuspended in PBS and subjected to immunoblot analysis to confirm the expression of eVLPs. As shown in [Fig. 2](#fig0010){ref-type="fig"}C, viral proteins were detected in the VLP pellets; analysis of the formation of eVLPs by TEM is ongoing.Fig. 2(A) Diagram of sucrose gradient ultracentrifugation of VLPs. (B) Detection of eVLP in fractions. S2 cells were transfected with genes of EBOV *Makona*, and the harvested cells were disrupted by repeated cycles of freezing and thawing. The S2 cell lysates were subjected to sucrose gradient ultracentrifugation, and 12 fractions were collected (top to bottom). eVLPs in the fraction were analyzed by immunoblotting. (C). Detection of eVLP in fractions 8 and 9. Fractions 8 and 9 were overlaid on top of the sucrose cushion and were ultracentrifuged. The pelleted eVLPs were subjected to immunoblot analysis to confirm the eVLPs.Fig. 2

Collectively, these findings showed that eVLPs were effectively produced in an S2 cell system and that the S2 cell system may be a promising strategy for effective production of eVLPs.

VLPs have been produced in several expression systems and have been shown to provide protective effects against EBOV infection in animal model. Vaccination with 293 T cell derived-Ebola VLPs protects nonhuman primates (NHPs) or rodents from EBOV infection ([@bib0125], [@bib0130],[@bib0135]; [@bib0110]). Antibodies against EBOV are produced in serum of cynomolgus macaques vaccinated with 293 T cell-derived eVLPs. High active specific antibodies against EBOV are produced in serum of cynomolgus macaques vaccinated with 293 T cell-derived eVLPs. Additionally, tumor necrosis factor (TNF)-α production in eVLP-vaccinated individuals is strongly increased in CD44 + T cells ([@bib0130],[@bib0135]). Immunization with KUN-VLPs generated by transfection with KUN replicon RNA containing EBOV GP protects *Makona* pigs and NHPs from challenge with EBOV infection ([@bib0090]; [@bib0085]). Moreover, in previous works, eVLPs have been produced in insect systems, resulting in activation of the immune response. VLPs produced in Sf9 cells using a baculovirus system stimulated cytokine secretion in dendritic cells, and immunization of mice with the VLPs increased IgG2a antibody production through induction of the Th1-biased immune response ([@bib0155]). In a previous report, high yields of HIV-1 VLPs were produced in HIV-1 envelope protein-overexpressing S2 cells, resulting in proper cleavage of envelope precursor protein ([@bib0150]). Therefore, we suggested that S2 cells may be a promising system for efficient production of eVLPs.

In this study, we used S2 cells for the production of VLPs and examined eVLPs production following overexpression of EBOV proteins. We showed that viral proteins of EBOV *Makona* were efficiently expressed in S2 cells and confirmed the formation of eVLPs by TEM. We purified eVLPs by sucrose gradient ultracentrifugation. Collectively, our findings suggested that the eVLPs produced by the S2 cell system in this study may be useful for the development of efficient VLP-based vaccines against EBOV. To the best of our knowledge, this is the first successful demonstration of VLP production from the new outbreak strain in the S2 expression system. Further *in vivo* studies on the VLPs of EBOV are necessary to characterize immune responses to this EBOV strain and to study the protective effects of VLP-based vaccines against EBOV infection.
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